Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Joan B. Erland"'
Autor:
Dana S. Thompson, Joan B. Erland, John D. Hainsworth, Thomas W. Twele, James E. Bradof, M. Patrick Stagg, John H. Barton, F. Anthony Greco
Publikováno v:
Clinical Lung Cancer. 5:33-38
The purpose of this study was to evaluate the feasibility, toxicity, and efficacy of the combination of weekly docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer (NSCLC) who are either elderly or have poor performance stat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec8f4ebb9258cde541dbfe68e7cbf47e
https://doi.org/10.3816/clc.2003.n.019
https://doi.org/10.3816/clc.2003.n.019
Autor:
Lisa H. Morrissey, John H. Barton, Sharlene Litchy, Daniel C. Scullin, John D. Hainsworth, Howard A. Burris, Joan B. Erland, Paul Richards, F. Anthony Greco, James E. Bradof
Publikováno v:
Journal of Clinical Oncology. 20:1651-1656
PURPOSE: To evaluate the efficacy and toxicity of the novel chemotherapy combination that includes gemcitabine, carboplatin, and paclitaxel in the treatment of patients with carcinoma of unknown primary site. PATIENTS AND METHODS: One hundred twenty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3313f85212549dd168c9f2f5869193c
https://doi.org/10.1200/jco.2002.20.6.1651
https://doi.org/10.1200/jco.2002.20.6.1651
Autor:
Joan B. Erland, Lisa H. Morrissey, Steven W. Smith, F. Anthony Greco, David Rinaldi, Howard A. Burris, John D. Hainsworth, J. R. Gray, Charles Dobbs, Sharlene Litchy, Eric L. Raefsky
Publikováno v:
Cancer. 92:2142-2147
BACKGROUND The objective of this study was to determine the feasibility and toxicity of paclitaxel and carboplatin given in the adjuvant setting alone for patients with resected Stage IB disease and combined with radiotherapy for patients with resect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c0964614e1cdad47a281a69b1c35213
https://doi.org/10.1002/1097-0142(20011015)92:8<2142::aid-cncr1556>3.0.co
https://doi.org/10.1002/1097-0142(20011015)92:8<2142::aid-cncr1556>3.0.co
Autor:
John D. Hainsworth, Sharlene Litchy, F. Anthony Greco, Howard A. Burris, Jeremy K. Hon, Joan B. Erland, Joseph E. Brierre
Publikováno v:
Cancer. 88:1353-1358
BACKGROUND Second-line chemotherapy for patients with nonsmall cell lung carcinoma has been ineffective due to the lack of activity of older agents following platinum-based therapy. This Phase II trial evaluated the feasibility, toxicity, and efficac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee92af18e85d6113646b7e994c54eff2
https://doi.org/10.1002/(sici)1097-0142(20000315)88:6<1353::aid-cncr11>3.0.co
https://doi.org/10.1002/(sici)1097-0142(20000315)88:6<1353::aid-cncr11>3.0.co
Autor:
Leonard A. Kalman, F. Anthony Greco, Marshall T. Schreeder, Howard A. Burris, James R. Gray, Joan B. Erland, John D. Hainsworth
Publikováno v:
Cancer. 89:2655-2660
BACKGROUND The long term survival and toxicity associated with the chemotherapy combination of paclitaxel, carboplatin, and extended-schedule etoposide used for the treatment of patients with metastatic carcinoma of unknown primary site were evaluate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd3facfd46d505491231f7699487d995
https://doi.org/10.1002/1097-0142(20001215)89:12<2655::aid-cncr19>3.0.co
https://doi.org/10.1002/1097-0142(20001215)89:12<2655::aid-cncr19>3.0.co
Autor:
Jeremy K. Hon, L A Kalman, Daniel C. Scullin, Howard A. Burris, A. A. Meluch, Joan B. Erland, John D. Hainsworth, Steven W. Smith, Lisa H. Morrissey, F. Anthony Greco
Publikováno v:
Cancer. 85:1269-1276
BACKGROUND The combination of paclitaxel and carboplatin is widely used in the treatment of patients with advanced nonsmall cell lung carcinoma. In this Phase I/II study the authors evaluated the feasibility, toxicity, and efficacy of adding a third
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::491b2039e20cfae61de4ec6869a7c2fd
https://doi.org/10.1002/(sici)1097-0142(19990315)85:6<1269::aid-cncr8>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19990315)85:6<1269::aid-cncr8>3.0.co
Publikováno v:
Journal of Clinical Oncology. 16:2164-2168
PURPOSE Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients treated with a dose of 100 mg/m2 every 3 weeks. Recent experience with weekly paclitaxel has demonstrated a bone marrow-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97deb87cbb1fd00f90bb9355edecc591
https://doi.org/10.1200/jco.1998.16.6.2164
https://doi.org/10.1200/jco.1998.16.6.2164
Autor:
Geetha Joseph, Howard A. Burris, Lisa H. Morrissey, F. Anthony Greco, David R. Spigel, Ellen Spremulli, Steven W. Corso, John D. Hainsworth, Joan B. Erland, D. S. Thompson
Publikováno v:
The oncologist. 10(9)
Purpose. To compare the combination of paclitaxel (Taxol®; Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com) and topotecan (Hycamtin®; Glaxo SmithKline, Philadelphia, http://www.gsk.com) with paclitaxel, carboplatin (Paraplatin®; Bristol-My
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f04f039224e2de058b8ec3d8d41cd6
https://pubmed.ncbi.nlm.nih.gov/16249353
https://pubmed.ncbi.nlm.nih.gov/16249353
Autor:
F. Anthony Greco, Lisa H. Morrissey, Denise A. Yardley, John D. Hainsworth, Gladys Rodriguez, Joan B. Erland, Howard A. Burris, Don W. Shaffer, Sharlene Litchy, Robert C. Hermann
Publikováno v:
The oncologist. 9(6)
Purpose. To evaluate the efficacy and toxicity of the sequential administration of paclitaxel (Taxol®; Bristol-Myers Squibb; Princeton, NJ), carboplatin (Paraplatin®; Bristol-Myers Squibb), and oral etoposide (VePesid®; Bristol-Myers Squibb) follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07e1e7b6d6455f5440310c3ffd9eb646
https://pubmed.ncbi.nlm.nih.gov/15561808
https://pubmed.ncbi.nlm.nih.gov/15561808
Autor:
Don W. Shaffer, Burris Ha rd, Baker M, F A Greco, John D. Hainsworth, Joan B. Erland, Daniel C. Scullin
Publikováno v:
Cancer investigation. 21(2)
The purpose of the study was to evaluate the combination of gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer. Between March 1998 and February 1999, 30 patients with relapsed or refractory sma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9e335074e6c9627424e9a54b5d5fc01
https://pubmed.ncbi.nlm.nih.gov/12743984
https://pubmed.ncbi.nlm.nih.gov/12743984